Details for Patent: 8,511,304

Which drugs does patent 8,511,304 protect, and when does it expire?

Patent 8,511,304 protects ANORO ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.

Protection for ANORO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-six patent family members in twenty-one countries.

Summary for Patent: 8,511,304

Title:	Medicament dispenser
Abstract:	There is provided a medicament dispenser for use with plural elongate form medicament carriers, each having multiple distinct medicament dose portions carried thereby, the dispenser having a dispensing mechanism for dispensing the distinct medicament dose portions carried by each of the plural medicament carriers. The mechanism comprises a receiving station for receiving each of the plural medicament carriers; a release for releasing a distinct medicament dose portion from each of the plural medicament carriers on receipt thereof by the receiving station; an outlet, positioned to be in communication with the distinct medicament dose portions releasable by said a release; and an indexer for individually indexing the distinct medicament dose portions of each of the plural medicament carriers.
Inventor(s):	Anderson; Gregor John McLennan (Ware, GB), Bonney; Stanley George (Ware, GB), Davies; Michael Birsha (Ware, GB), Lintell; Daniel Thomas De Sansmarez (Ware, GB), Wilson; Alan Anthony (Ware, GB)
Assignee:	Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:	10/502,519
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 8,511,304

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	No					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-001	May 10, 2013		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-002	Apr 30, 2015		RX	Yes	Yes					Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-001	Sep 18, 2017		RX	Yes	Yes					Y
Glaxosmithkline	TRELEGY ELLIPTA	fluticasone furoate; umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	209482-002	Sep 9, 2020		RX	Yes	Yes					Y

Foreign Priority and PCT Information for Patent: 8,511,304

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0201677.2	Jan 25, 2002

PCT Information
PCT Filed	January 22, 2003	PCT Application Number:	PCT/EP03/00598
PCT Publication Date:	July 31, 2003	PCT Publication Number:	WO03/061743

International Family Members for US Patent 8,511,304

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003236835
Australia	2003250166
Australia	2003254590
Australia	2003281751
Brazil	0306799
Brazil	0312725
Brazil	PI0306799